Effect of Curcumin-Piperine in Fatty Liver

The effect of Curcumin-Piperine supplementation on cardiometabolic factors, hepatic steatosis and fibrosis of fibroscan results and liver function in patients with non-alcoholic fatty liver disease: a randomized double-blind clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121216011763N42

Enrollment

Registered

2020-01-10

Start date

2019-12-21

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: A daily curcumin-piperine capsule(500 mg curcumin+ 5 mg piperine) will recive after meal for 12 weeks. Intervention 2: Control group: A daily placebo capsule(500 m

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Tendency to participate in the study People aged 18-65 years Patients with Non-alcoholic fatty liver (grade 3-1) diagnosed by ultrasound

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Patients with Alcoholic Fatty Liver Smoking People with heart , pulmonary and kidney diseases, hepatitis, cirrhosis, biliary and immune disorders, hypertension, hypothyroidism and Cushing's syndrome Consumption of lipid and glucose lowering medicine, Vitamin E, Vitamin D, Orsodeoxycholic acid, Phenytoin, Tamoxifen, Lithium, Corticosteroids and Methotrexate Weight loss and bariatric surgery in the last year

Design outcomes

Primary

Measure	Time frame
Waist circumference. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: non-stretching tape measure.;BMI. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Dividing the weight into kilograms by squared height by meter.;ALT. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic photometric method.;AST. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic photometric method.;Hepatic steatosis and fibrosis. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Fibroscan.;TG. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;TC. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;HDL. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;LDL. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;Weight. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Digital scale.	—

Measure

Time frame

Waist circumference. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: non-stretching tape measure.;BMI. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Dividing the weight into kilograms by squared height by meter.;ALT. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic photometric method.;AST. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic photometric method.;Hepatic steatosis and fibrosis. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Fibroscan.;TG. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;TC. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;HDL. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;LDL. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;Weight. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Digital scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamreza Askari

Esfahan University of Medical Sciences

askari@mui.ac.ir+98 31 3668 1378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026